Beam Therapeutics BEAM

HealthcareMarket cap $2B2 connections

Beam Therapeutics is pioneering base editing - a next-generation gene editing technology that makes precise single-letter changes to DNA without cutting the double helix (avoiding the imprecision of CRISPR cutting). Its lead program targets sickle cell disease. Base editing could fix thousands of genetic diseases caused by single-letter DNA errors.

Explore Beam Therapeutics on the interactive map Relationship timeline Find a path to another company

Partners 2

Strategic partnerships, joint products and alliances

AmgenHealthcare · $160BAmgen base editing research collaboration
CRISPR TherapeuticsHealthcare · $4BCompeting next-gen gene editing modalities

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Beam Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=BEAM" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Beam Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.